Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S4.01
P/E—
Fwd P/E17.81
PEG2.11
52W— – —
RSI—
Target$118.42 (+9.6%)
Beta0.61
Div2.31%
Loading chart…
RSI (14)
Loading patterns…
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 74
Overbought · 100
Signal
Overbought
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
5Bullish
1Bearish
0Neutral
▲ Double Bottom — Two lows ~$82.88 — bullish reversal confirmed
▲ Double Bottom — Two lows ~$85.41 — bullish reversal confirmed
▲ Bull Flag — Breakout after +10% pole — bullish continuation
▲ Double Bottom — Two lows ~$87.05 — bullish reversal confirmed
▲ Bull Flag — Breakout after +15% pole — bullish continuation
▼ Bear Flag — Breakdown after -11% pole — bearish continuation
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$118.42
+9.6% upside
Low $103
—
High $135
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| UBS | Buy | — | ↔ Maintain | 2026-07-28 |
| Citigroup | Buy | — | ↔ Maintain | 2026-07-17 |
| Piper Sandler | Overweight | — | ↔ Reiterate | 2026-07-17 |
| JP Morgan | Overweight | — | ↔ Maintain | 2026-07-17 |
| Wells Fargo | Overweight | — | ↔ Maintain | 2026-07-17 |
| TD Cowen | Buy | — | ↔ Reiterate | 2026-07-17 |
| Evercore ISI Group | Outperform | — | ↔ Maintain | 2026-07-17 |
| RBC Capital | Outperform | — | ↔ Reiterate | 2026-07-17 |
| BTIG | Buy | — | ↔ Maintain | 2026-07-17 |
| Baird | Outperform | — | ● Initiate | 2026-07-01 |
| Barclays | Overweight | — | ↔ Maintain | 2026-04-20 |
| Oppenheimer | Outperform | — | ↔ Maintain | 2026-04-17 |
| Benchmark | Buy | — | ↔ Maintain | 2026-04-17 |
| B of A Securities | Buy | — | ↔ Maintain | 2026-04-17 |
| Stifel | Buy | — | ↔ Maintain | 2026-04-17 |
| Goldman Sachs | Buy | — | ↔ Maintain | 2026-04-09 |
| Freedom Broker | Buy | Hold → Buy | ▲ Upgrade | 2026-01-29 |
| Bernstein | Outperform | — | ↔ Maintain | 2026-01-23 |
UBS
2026-07-28
Buy
↔ Maintain
Citigroup
2026-07-17
Buy
↔ Maintain
Piper Sandler
2026-07-17
Overweight
↔ Reiterate
JP Morgan
2026-07-17
Overweight
↔ Maintain
Wells Fargo
2026-07-17
Overweight
↔ Maintain
TD Cowen
2026-07-17
Buy
↔ Reiterate
Evercore ISI Group
2026-07-17
Outperform
↔ Maintain
RBC Capital
2026-07-17
Outperform
↔ Reiterate
BTIG
2026-07-17
Buy
↔ Maintain
Baird
2026-07-01
Outperform
● Initiate
Barclays
2026-04-20
Overweight
↔ Maintain
Oppenheimer
2026-04-17
Outperform
↔ Maintain
Benchmark
2026-04-17
Buy
↔ Maintain
B of A Securities
2026-04-17
Buy
↔ Maintain
Stifel
2026-04-17
Buy
↔ Maintain
Goldman Sachs
2026-04-09
Buy
↔ Maintain
Freedom Broker
2026-01-29
Buy
(from Hold)
▲ Upgrade
Bernstein
2026-01-23
Outperform
↔ Maintain
Profitability
Gross Margin
56.77%TTM
Op. Margin
14.15%TTM
ROE
N/ATTM
Rev. Growth
13.00%YoY
Free Cash Flow
N/ATTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
64.77MRQ
Current Ratio
N/AMRQ
Cash
7.30BMRQ
Total Debt
34.14BMRQ
Net Debt
—MRQ
Income
Div. Yield
2.31%TTM
Annual Rate
2.52Fwd
Payout Ratio
78.96%TTM
Dividend History
Payout Ratio (TTM): 78.96%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-07-15 | $0.6300 | 0.71% |
| 2026-04-15 | $0.6300 | 0.62% |
| 2026-01-15 | $0.6300 | 0.52% |
| 2025-10-15 | $0.5900 | 0.46% |
| 2025-07-15 | $0.5900 | 0.46% |
| 2025-04-15 | $0.5900 | 0.48% |
| 2025-01-15 | $0.5900 | 0.55% |
| 2024-10-15 | $0.5500 | 0.49% |
| 2024-07-15 | $0.5500 | 0.56% |
| 2024-04-12 | $0.5500 | 0.53% |
| 2024-01-11 | $0.5500 | 0.51% |
| 2023-10-12 | $0.5100 | 0.60% |
| 2023-07-13 | $0.5100 | 0.50% |
| 2023-04-13 | $0.5100 | 0.53% |
| 2023-01-12 | $0.5100 | 0.49% |
| 2022-10-13 | $0.4700 | 0.49% |
| 2022-07-14 | $0.4700 | 0.48% |
| 2022-04-13 | $0.4700 | 0.43% |
| 2022-01-13 | $0.4700 | 0.40% |
| 2021-10-14 | $0.4500 | 0.42% |
| 2021-07-14 | $0.4500 | 0.42% |
| 2021-04-14 | $0.4500 | 0.41% |
| 2021-01-14 | $0.4500 | 0.45% |
| 2020-10-14 | $0.3600 | 0.37% |
| 2020-07-14 | $0.3600 | 0.42% |
| 2020-04-14 | $0.3600 | 0.45% |
| 2020-01-14 | $0.3600 | 0.47% |
| 2019-10-11 | $0.3200 | 0.46% |
| 2019-07-12 | $0.3200 | 0.43% |
| 2019-04-12 | $0.3200 | 0.47% |
| 2019-01-14 | $0.3200 | 0.54% |
| 2018-10-12 | $0.2800 | 0.47% |
| 2018-07-12 | $0.2800 | 0.52% |
| 2018-04-12 | $0.2800 | 0.55% |
| 2018-01-11 | $0.2800 | 0.55% |
| 2017-10-12 | $0.2650 | 0.57% |
| 2017-07-12 | $0.2650 | 0.65% |
| 2017-04-11 | $0.2650 | 0.72% |
| 2017-01-11 | $0.2650 | 0.77% |
| 2016-10-12 | $0.2600 | 0.76% |
How ABT Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 186.88B |
| Enterprise Value | 215.60B |
| Trailing P/E | 34.95 |
| Forward P/E | 17.81 |
| PEG Ratio (5yr) | 2.11 |
| Price/Sales (ttm) | 4.01 |
| Price/Book (mrq) | 3.61 |
| EV/Revenue | 4.63 |
| EV/EBITDA | 18.17 |
Share Statistics
| Avg Vol (3m) | 13.39M |
| Shares Outstanding | 1.73B |
| Float | 1.73B |
| % Held by Insiders | 0.49% |
| % Held by Institutions | 82.52% |
| Short Ratio | 1.83 |
| Short % of Float | 1.59% |
Profitability
| Gross Margin | 56.77% |
| Operating Margin (ttm) | 14.15% |
| Profit Margin | 11.65% |
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 46.58B |
| Revenue Growth (yoy) | 13.00% |
| Gross Profit (ttm) | 26.45B |
| EBITDA | 11.87B |
| Net Income (ttm) | 5.40B |
| Diluted EPS (ttm) | 3.09 |
| EPS Growth (yoy) | -47.50% |
Balance Sheet
| Total Cash (mrq) | 7.30B |
| Total Debt (mrq) | 34.14B |
| Debt / Equity (mrq) | 64.77 |
| Current Ratio (mrq) | N/A |
| Book Value / Share | 29.89 |
| Operating CF (ttm) | N/A |
| Free Cash Flow (ttm) | N/A |
Trading & Dividends
| Beta (5Y) | 0.61 |
| 50-Day MA | 92.14 |
| 200-Day MA | 108.74 |
| Fwd Dividend Yield | 235.00% |
| Payout Ratio | 78.96% |
Ownership Breakdown
Institutional 82.52%
Insider 0.49%
Public 17.0%
Short Interest
1.59% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in ABT in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-07 | STRATTON JOHN G. | Director | Purchase at price 86.82 per share. | 2,000 | $173,640 |
| 2026-04-27 | STARKS DANIEL J | Director | Purchase at price 92.65 per share. | 10,000 | $926,537 |
| 2026-04-24 | ROMAN MICHAEL F | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | KUMBIER MICHELLE A | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | MCKINSTRY NANCY | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | CONROY KEVIN T | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | O GRADY MICHAEL G | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | BLOUNT SALLY E | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | STRATTON JOHN G. | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | GONZALEZ PATRICIA PAOLA | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | AHUJA NITA M.D. | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | MCDEW DARREN W | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | BABINEAUX CLAIRE FONTENOT | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-24 | STARKS DANIEL J | Director | Stock Award(Grant) at price 0.00 per share. | 2,286 | — |
| 2026-04-23 | BOUDREAU PHILIP P | Chief Financial Officer | Purchase at price 91.50 per share. | 2,200 | $201,300 |
| 2026-03-23 | ORVILLE JACOB A | Officer | Stock Award(Grant) at price 0.00 per share. | 13,255 | — |
| 2026-03-02 | SALVADORI DANIEL GESUA SIVE | Officer | Sale at price 115.58 per share. | 885 | $102,288 |
| 2026-03-02 | MCCOY JOHN A. JR | Officer | Sale at price 115.58 per share. | 585 | $67,614 |
| 2026-03-02 | SHROFF ERIC | Officer | Sale at price 115.58 per share. | 709 | $81,946 |
| 2026-03-02 | CUSHMAN ELIZABETH C | General Counsel | Sale at price 115.58 per share. | 263 | $30,398 |
| 2026-03-02 | MORELAND MARY K | Officer | Sale at price 115.58 per share. | 613 | $70,851 |
| 2026-03-02 | MORRONE LOUIS H | Officer | Sale at price 115.58 per share. | 1,144 | $132,224 |
| 2026-02-24 | FORD ROBERT B. | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 83,464 | — |
| 2026-02-24 | MCCOY JOHN A. JR | Officer | Stock Award(Grant) at price 0.00 per share. | 5,373 | — |
| 2026-02-24 | SALVADORI DANIEL GESUA SIVE | Officer | Stock Award(Grant) at price 0.00 per share. | 21,644 | — |
STRATTON JOHN G.
Director
Purchase at price 86.82 per share.
2026-05-07
2,000 sh
$173,640
STARKS DANIEL J
Director
Purchase at price 92.65 per share.
2026-04-27
10,000 sh
$926,537
ROMAN MICHAEL F
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
KUMBIER MICHELLE A
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
MCKINSTRY NANCY
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
CONROY KEVIN T
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
O GRADY MICHAEL G
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
BLOUNT SALLY E
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
STRATTON JOHN G.
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
GONZALEZ PATRICIA PAOLA
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
AHUJA NITA M.D.
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
MCDEW DARREN W
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
BABINEAUX CLAIRE FONTENOT
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
STARKS DANIEL J
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-24
2,286 sh
—
BOUDREAU PHILIP P
Chief Financial Officer
Purchase at price 91.50 per share.
2026-04-23
2,200 sh
$201,300
ORVILLE JACOB A
Officer
Stock Award(Grant) at price 0.00 per share.
2026-03-23
13,255 sh
—
SALVADORI DANIEL GESUA SIVE
Officer
Sale at price 115.58 per share.
2026-03-02
885 sh
$102,288
MCCOY JOHN A. JR
Officer
Sale at price 115.58 per share.
2026-03-02
585 sh
$67,614
SHROFF ERIC
Officer
Sale at price 115.58 per share.
2026-03-02
709 sh
$81,946
CUSHMAN ELIZABETH C
General Counsel
Sale at price 115.58 per share.
2026-03-02
263 sh
$30,398
MORELAND MARY K
Officer
Sale at price 115.58 per share.
2026-03-02
613 sh
$70,851
MORRONE LOUIS H
Officer
Sale at price 115.58 per share.
2026-03-02
1,144 sh
$132,224
FORD ROBERT B.
Chief Executive Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-24
83,464 sh
—
MCCOY JOHN A. JR
Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-24
5,373 sh
—
SALVADORI DANIEL GESUA SIVE
Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-24
21,644 sh
—